J&J's Janssen Seeks FDA OK for Expanded Imbruvica Use

Date : 11/08/2019 @ 1:27PM
Source : Dow Jones News
Stock : AbbVie Inc (ABBV)
Quote : 87.84  -0.89 (-1.00%) @ 12:59AM
After Hours
Last Trade
Last $ 87.90 ▲ 0.06 (0.07%)

J&J's Janssen Seeks FDA OK for Expanded Imbruvica Use

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it filed a supplemental new-drug application with the U.S. Food and Drug Administration for the expanded use of the cancer drug Imbruvica.

Janssen said it is seeking approval of Imbruvica in combination with rituximab for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The company said the filing is based on positive results from a phase 3 study of the combination that met the primary endpoints of progression-free survival and overall survival compared to the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab.

Imbruvica, which is jointly developed and commercialized by J&J's Janssen Biotech Inc. unit and AbbVie Inc.'s (ABBV) Pharmacyclics LLC, was first approved by the FDA in 2013 and is currently indicated in six disease areas.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

November 08, 2019 08:12 ET (13:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.